Drug Regulation Rosiglitazone: what went wrong?

被引：78

作者：

Cohen, Deborah

机构：

来源：

BRITISH MEDICAL JOURNAL | 2010年 / 341卷

关键词：

D O I：

10.1136/bmj.c4848

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

[No abstract available]

引用

页码：530 / 535

页数：9

共 25 条

[1]

*AM DIAB ASS, FDA REV DAT 2 NEW DI

[2]

CALABRESI M, 1916, TIME 0816

[3]

Department of Health and Human Services, 2010, ADV COMM M NDA 21071

[4] The Risk of Fractures Associated with Thiazolidinediones: A Self-controlled Case-Series Study [J].

Douglas, Ian J. ;

Evans, Stephen J. ;

Pocock, Stuart ;

Smeeth, Liam .

PLOS MEDICINE, 2009, 6 (09)

[5]

*EUR MED AG, 2001, EPAR AV

[6]

*EUR MED AG, AV PROC STEPS TAK SC

[7] Lessons from the glitazones: a story of drug development [J].

Gale, EAM .

LANCET, 2001, 357 (9271) :1870-1875

[8]

Harris G., 2010, NY TIMES 0713

[9] Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial [J].

Home, Philip D. ;

Pocock, Stuart J. ;

Beck-Nielsen, Henning ;

Curtis, Paula S. ;

Gomis, Ramon ;

Hanefeld, Markolf ;

Jones, Nigel P. ;

Komajda, Michel ;

McMurray, John J. V. .

LANCET, 2009, 373 (9681) :2125-2135

[10] Thiazolidinediones for type 2 diabetes - New agents reduce insulin resistance but need long term clinical trials [J].

Krentz, AJ ;

Bailey, CJ ;

Melander, A .

BMJ-BRITISH MEDICAL JOURNAL, 2000, 321 (7256) :252-253

← 1 2 3 →